Search
Dynavax Technologies Corp
DVAXAdd to Watchlist
15.500USD
0.0000.00%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
1.76BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
0.00%
1 Month
0.00%
6 Months
+0.78%
Year to Date
+0.78%
1 Year
+54.08%
Key Figures
--Open
0.000High
0.00Volume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
45.37%Turnover Ratio
15.500Prev. Close
0.000Low
0.00Turnover
8.89P/E Static
0.45P/B
0.00%Div Yield TTM
-4.32%ROA
15.73052wk High
2.47Volume Ratio
27.31MNet Profit
15.66MShares
-0.3637EPS TTM
0.93Beta
-7.14%ROE
9.20052wk Low
0.06%Amplitude
84.82%Gross Margin
1.76BMarket Cap
0.27Reward/Risk
2.15%Risk Rate
TradingKey Stock Score of Dynavax Technologies Corp
Currency: USD Updated: 2026-02-09Key Insights
Dynavax Technologies Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 41 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 20.50.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Dynavax Technologies Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Dynavax Technologies Corp Highlights
StrengthsRisks
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company developing and commercializing vaccines to help protect against infectious diseases. The Company has two commercial products: HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), and CpG 1018 adjuvant. The HEPLISAV-B vaccine is used for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose in-one-month adult hepatitis B vaccine. CpG 1018 adjuvant is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. The Company is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. Its pipeline programs include Shingles vaccine program (Z-1018) and Plague vaccine program. Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Undervalued
The company’s latest PE is -42.61, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 115.66M shares, decreasing 9.06% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 2.65K shares of this stock.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
16.000
Target Price
+3.23%
Upside Space
Dynavax Technologies Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Dynavax Technologies Corp Info
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company developing and commercializing vaccines to help protect against infectious diseases. The Company has two commercial products: HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), and CpG 1018 adjuvant. The HEPLISAV-B vaccine is used for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose in-one-month adult hepatitis B vaccine. CpG 1018 adjuvant is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. The Company is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. Its pipeline programs include Shingles vaccine program (Z-1018) and Plague vaccine program. Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.
Ticker SymbolDVAX
CompanyDynavax Technologies Corp
CEOSpencer (Ryan)
Websitehttps://www.dynavax.com/
Related Instruments
-0.64%
-0.05%
-0.23%
-1.64%
-2.41%
-2.95%
-0.22%
+1.75%
-0.29%
-0.79%
+0.26%
-2.00%
-2.10%
-2.41%
+1.68%
0.00%
+0.19%
-1.97%
+0.06%
-0.44%Popular Instruments
52269.200
+14.900 (+0.03%)
29649.000
-150.300 (-0.50%)
7473.600
-1.900 (-0.03%)
14790.000
-565.000 (-3.68%)
68484.000
-1001.000 (-1.44%)
6286.900
+11.500 (+0.18%)
68.014
+0.046 (+0.07%)
294.380
+5.020 (+1.73%)
197.580
-2.510 (-1.25%)
4071.860
+41.090 (+1.02%)
FAQs
What is the current price of Dynavax Technologies Corp (DVAX)?
The current price of Dynavax Technologies Corp (DVAX) is 15.50.
What is the symbol of Dynavax Technologies Corp?
The ticker symbol of Dynavax Technologies Corp is DVAX.
What is the 52-week high of Dynavax Technologies Corp?
The 52-week high of Dynavax Technologies Corp is 15.73.
What is the 52-week low of Dynavax Technologies Corp?
The 52-week low of Dynavax Technologies Corp is 9.20.
What is the market capitalization of Dynavax Technologies Corp?
The market capitalization of Dynavax Technologies Corp is 1.76B.
Is Dynavax Technologies Corp (DVAX) currently rated as Buy, Hold, or Sell?
According to analysts, Dynavax Technologies Corp (DVAX) has an overall rating of Buy, with a price target of 16.00.
What is the Earnings Per Share (EPS TTM) of Dynavax Technologies Corp (DVAX)?
The Earnings Per Share (EPS TTM) of Dynavax Technologies Corp (DVAX) is 0.21.